Center-Authored Papers

Filters: Author is Fisher, Richard I  [Clear All Filters]
Journal Article
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2015.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):326-62. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE, Fisher RI et al..  2016.  Diffuse Large B-Cell Lymphoma Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(2):196-231. Abstract
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, Leblanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK et al..  2014.  Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.. American journal of hematology. Abstract
Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW et al..  2003.  Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(18):3512-9. Abstract
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI.  2004.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(21):4302-11. Abstract
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L et al..  2015.  Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13):1482-90. Abstract
Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI.  2009.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(1):114-9. Abstract
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Caimi P, Fayad LE et al..  2017.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3):293-311. Abstract
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Fayad LE et al..  2016.  NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(9):1067-79. Abstract
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.  2005.  New treatment options have changed the survival of patients with follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(33):8447-52. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Bellam N, Byrd JC, Czuczman MS et al..  2014.  Non-Hodgkin's Lymphomas, Version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(6):916-46. Abstract
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP.  2012.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.. Cancer. Abstract
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM et al..  2015.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox A-M et al..  2016.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.. Leukemia & lymphoma. 57(10):2359-2369. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Till BG, Li H, Bernstein SH, Fisher RI, Burack RW, Rimsza LM, Floyd JD, Dasilva MA, Moore DF, Pozdnyakova O et al..  2016.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.. British journal of haematology. 172(2):208-218. Abstract
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.  2012.  A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.. Blood. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20. Abstract